Fusion Antibodies (LON:FAB) Sets New 1-Year Low – What’s Next?

Fusion Antibodies plc (LON:FAB)’s stock price hit a new 52-week low on Wednesday. The company traded as low as GBX 4 and last traded at GBX 4.30, with a volume of 3,253,285 shares. The stock had previously closed at GBX 4.25.

Fusion Antibodies Stock Performance

The company has a market cap of £5.38 million, a P/E ratio of -4.30 and a beta of 1.24. The company’s 50-day moving average is GBX 9.07 and its two-hundred day moving average is GBX 11.68. The company has a quick ratio of 2.36, a current ratio of 2.82 and a debt-to-equity ratio of 20.41.

Fusion Antibodies (LON:FAB) last announced its quarterly earnings data on Monday, September 14th. The company reported GBX (1.20) EPS for the quarter. Fusion Antibodies had a negative return on equity of 97.87% and a negative net margin of 54.45%. Equities analysts predict that Fusion Antibodies plc will post -130.00 EPS for the current year.

Fusion Antibodies Company Profile

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications. The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion’s proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials.